BOSTON, December 16, 2015— Rhythm, a biopharmaceutical company developing peptide therapeutics for rare genetic metabolic disorders, announced today that the company has appointed David Meeker, MD, and David McGirr to its Board of Directors. Dr. Meeker is President and Chief Executive Officer of Genzyme, and Mr. McGirr is former Chief Financial Officer of Cubist Pharmaceuticals.
“We are delighted to welcome David Meeker and David McGirr to our Board,” said Keith Gottesdiener, CEO of Rhythm. “David Meeker’s experience leading Genzyme’s rare disease business and David McGirr’s expertise as a leading biotech CFO will be very important to Rhythm as we build our business and advance the setmelanotide program in clinical trials for rare genetic disorders of obesity.”
David Meeker, MD, is President and Chief Executive Officer of Genzyme, a subsidiary of Sanofi. He leads Genzyme’s two business units—rare diseases and multiple sclerosis—as well as the company’s relationships with patient communities and workforce of nearly 6,000 employees. As an Executive Vice President of Sanofi, he is a member of Sanofi’s Executive Committee. Prior to joining Genzyme in 1994, Dr. Meeker was Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an Assistant Professor of Medicine at Ohio State University. Dr. Meeker received his MD from the University of Vermont Medical School.
David McGirr was a Senior Advisor to the Chief Executive Officer of Cubist Pharmaceuticals until June 2014 and a Senior Vice President and Chief Financial Officer of Cubist from 2002 to 2013. Prior to joining Cubist, Mr. McGirr was President and Chief Operating Officer of hippo inc, an internet technology company and, previously, President and Chief Executive Officer of GAB Robins North America, Inc., a risk management company. Mr. McGirr received a BSc in Civil Engineering from the University of Glasgow and an MBA from The Wharton School at the University of Pennsylvania.
About Rhythm (www.rhythmtx.com)
Rhythm is a biopharmaceutical company focused on developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life‑threatening metabolic disorders. Rhythm’s lead peptide product candidate is setmelanotide, a first‑in‑class melanocortin‑4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. The company is based in Boston, Massachusetts.